China's Bio-Thera gets approval for Humira biosimilar

China's Bio-Thera gets approval for Humira biosimilar
Reuters: Health
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market.


No comments:

Post a Comment